Skip to main content
. 2020 Sep 4;69(5):1–18. doi: 10.15585/mmwr.ss6905a1

FIGURE 1.

This figure is a bar chart showing the use of continuous prophylaxis among males with severe hemophilia in 2005, 2010, 2015, and 2018. Use of prophylactic treatment regimens has markedly increased in recent years across all age groups and for both hemophilia A and B.

Percentage* of male registry participants with severe hemophilia who used a continuous prophylaxis† treatment regimen, by hemophilia type and patient age — Universal Data Collection surveillance system (2005 and 2010) and Community Counts surveillance system (2015 and 2018), United States

* Data for this figure are available (Supplementary Table 1; https://stacks.cdc.gov/view/cdc/85148).

† Patients were considered to be using continuous prophylaxis if the hemophilia treatment center provider indicated that the patient regularly used a treatment product to prevent bleeding episodes (even if the patient did not completely adhere to the regimen) and that the patient was expected continue with this regimen indefinitely.